356 results on '"Monif, Mastura"'
Search Results
2. Language impairments in seropositive and seronegative autoimmune encephalitis
3. Characterizing cognitive function in patients with autoimmune encephalitis: an Australian prospective study
4. P2X7 receptor antagonism by AZ10606120 significantly depletes glioblastoma cancer stem cells in vitro
5. CLADIN- CLADribine and INnate immune response in multiple sclerosis – A phase IV prospective study
6. Cognitive and psychopathological features of neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease: A narrative review
7. MicroRNAs in adult high-grade gliomas: Mechanisms of chemotherapeutic resistance and their clinical relevance
8. Risks and outcomes of pregnancy in neuromyelitis optica spectrum disorder: A comprehensive review
9. Neutropaenia complications from Ocrelizumab and Rituximab treatment
10. Neuroimaging characteristics may aid in diagnosis, subtyping, and prognosis in autoimmune encephalitis
11. P2X7 receptor antagonism by AZ10606120 significantly reduced in vitro tumour growth in human glioblastoma
12. A comprehensive review of the advances in neuromyelitis optica spectrum disorder
13. Cognition following chimeric antigen receptor T-cell therapy: A systematic review
14. Serum neurofilament light as a biomarker of vulnerability to a second mild traumatic brain injury
15. Psychiatric manifestations of autoimmune encephalitis
16. Rare antibody-mediated and seronegative autoimmune encephalitis: An update
17. Prevalence, risk factors, and prognosis of drug-resistant epilepsy in autoimmune encephalitis
18. Contemporary advances in antibody-mediated encephalitis: anti-LGI1 and anti-Caspr2 antibody (Ab)-mediated encephalitides
19. Contemporary advances in anti-NMDAR antibody (Ab)-mediated encephalitis
20. The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study.
21. Electroclinical biomarkers of autoimmune encephalitis
22. Failure of alemtuzumab therapy in three patients with MOG antibody associated disease
23. Cognitive and psychopathological outcomes in acute disseminated encephalomyelitis
24. Relapse Determinants in Seropositive and Seronegative Neuromyelitis Optica Spectrum Disorder (P10-14.016)
25. Real-world efficacy, roll-out and uptake of intramuscular tixagevimab/cilgavimab as COVID-19 pre-exposure prophylaxis in people with multiple sclerosis and neuroimmunological conditions during the COVID-19 pandemic
26. Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study
27. Clinical outcomes among initial survivors of cryptogenic new-onset refractory status epilepsy (NORSE)
28. Antagonism of the ATP-gated P2X7 receptor: a potential therapeutic strategy for cancer
29. Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
30. The need to incorporate aged animals into the preclinical modeling of neurological conditions
31. Clinical outcomes among initial survivors of cryptogenic new‐onset refractory status epilepsy (NORSE)
32. Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies
33. The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease
34. P2X7 receptor antagonism inhibits tumour growth in human high-grade gliomas
35. Inflammatory complications of CGRP monoclonal antibodies: a case series
36. Risks and outcomes of pregnancy in neuromyelitis optica spectrum disorder: A comprehensive review
37. Repetitive mild traumatic brain injury elicits a reactive microglial morphology and elevates serum neurofilament light levels, independent of NLRP3 inflammasome inhibition
38. Development and Validation of a Peripheral Cell Ratio and Lactate Score for Differentiating Status Epilepticus from Prolonged Psychogenic Non‐Epileptic Seizures
39. Cognitive and psychopathological outcomes in acute disseminated encephalomyelitis
40. 2623 Prevalence of movement disorders in autoimmune encephalitis: a systematic review and meta-analysis
41. 2710 Effects of purinergic P2X receptor 7 (P2X7R) inhibition in glioblastoma
42. 2808 Exploring the uptake, and real-world efficacy of intramuscular tixagevimab150mg/150mg cilgavimab (EvusheldTM) in multiple sclerosis patients (pwMS) during COVID 19 pandemic
43. 8 Cervical abnormality risk increases in women with MS treated with high-efficacy disease modifying therapy
44. 7 CLADIN: CLADribine and INnate immune responses in multiple sclerosis
45. 20 Changes in mRNA expression in the temporal lobe of patients with drug resistant epilepsy: a focus on neuroinflammation
46. 2785 Executive dysfunction in patients with autoimmune encephalitis – a study of Australian autoimmune encephalitis consortium
47. 6 Spike antibody seroconversion and emerging variant cross-reactivity following COVID-19 third vaccination dose in Australian people with multiple Sclerosis
48. 2781 Memory outcomes in patients with autoimmune encephalitis – a study of the Australian autoimmune encephalitis consortium
49. Movement disorders in cell surface antibody mediated autoimmune encephalitis: a meta-analysis
50. Clinical factors associated with the yield of routine outpatient scalp electroencephalograms: A retrospective analysis from a tertiary hospital
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.